VEGFA and hepatocellular carcinoma: Also, a combined therapy involving atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular endothelial growth factor (VEGF)) presents acceptable effects in HCC treatment [14].